.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,124,355

« Back to Dashboard

Claims for Patent: 6,124,355

Title: Oxybutynin therapy
Abstract:A composition comprising oxybutynin, a dosage form comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.
Inventor(s): Guittard; George V. (Palo Alto, CA), Jao; Francisco (Palo Alto, CA), Marks; Susan M. (Palo Alto, CA), Kidney; David J. (Palo Alto, CA), Gumucio; Fernando E. (Palo Alto, CA)
Assignee:
Application Number:09/078,192
Patent Claims: 1. A sustained-release oxybutynin formulation for oral administration to a patient comprising a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that delivers from 0 to 20% of the oxybutynin in 0 to 4 hours, from 20 to 50% of the oxybutynin in 0 to 8 hours, from 50 to 85% of the oxybutynin in 0 to 14 hours, and greater than 75% of the oxybutynin in 0 to 24 hours for treating incontinence in the patient.

2. A sustained-release oxybutynin formulation for oral administration to a patient in need of treatment for urge incontinence comprising a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that delivers from 0 to 1 mg in 0 to 4 hours, from 1 mg to 2.5 mg in 0 to 8 hours, from 2.75 to 4.25 mg in 0 to 14 hours, and 3.75 mg to 5 mg in 0 to 24 hours for treating urge incontinence in the patient.

3. A sustained-release oxybutynin solid dosage form for oral administration to a patient for treating incontinence comprising an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that administers up to 2 mg of the member in 0 to 4 hours, from 2 mg to 5 mg of the member in 0 to 8 hours, from 5 mg to 8.5 mg of the member in 0 to 14 hours, and greater than 7.5 mg in 0 to 24 hours for treating incontinence in the patient.

4. A sustained-release oxybutynin dosage form for oral administration to a patient for treating incontinence comprising an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that administers up to 3 mg in 0 to 4 hours, 3 mg to 7.5 mg in 0 to 8 hours, 8 mg to 13 mg in 0 to 14 hours, and 12 mg to 15 mg in 0 to 24 hours for treating incontinence in the patient.

5. A dosage form for the oral administration of oxybutynin to a patient for treating incontinence, wherein the dosage form comprises a therapeutic dose of oxybutynin that is administered in a sustained-release cumulative dose of 0.2% to 80% over 2 to 16 hours.

6. The dosage form for the oral administration of oxybutynin according to claim 5, wherein the dosage form comprises a dose of 5 mg to 20 mg of oxybutynin.

7. The dosage form for the oral administration of oxybutynin according to claim 5, wherein the dosage form is a pharmaceutically acceptable tablet.

8. A dosage form for the oral administration of oxybutynin to a patient for treating incontinence, wherein the dosage form comprises a therapeutic dose of oxybutynin that is administered in a sustained release rate of 0.5% to 7% per hour over 30 minutes to 22 hours.

9. The dosage form for the oral administration of oxybutynin according to claim 8, wherein the dosage form comprises a dose of 5 mg to 20 mg of oxybutynin.

10. The dosage form for the oral administration of oxybutynin according to claim 8, wherein the dosage form is a pharmaceutically acceptable solid tablet.

11. A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that is delivered from 0 to 20% of the dose in 0 to 4 hours, from 20 to 50% of the dose in 0 to 8 hours, from 50 to 85% of the dose in 0 to 14 hours, and greater than 75% of the dose in 0 to 24 hours for treating incontinence in the patient.

12. The method for treating incontinence in a patient according to claim 11, wherein the therapeutic dose is 1 mg to 100 mg.

13. A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt which oxybutynin is administered in from 0 to 1 mg in 0 to 4 hours, from 1 mg to 2.5 mg in 0 to 8 hours, from 2.75 to 4.25 mg in 0 to 14 hours, and 3.75 mg to 5 mg in 0 to 24 hours for treating incontinence in the patient.

14. A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin and its pharmaceutically acceptable salt, which oxybutynin is administered in up to 2 mg in 0 to 4 hours, 2 mg to 5 mg in 0 to 8 hours, 5 mg to 8 mg in 8.5 mg in 0 to 14 hours, and greater than 7.5 mg in 0 to 24 hours for treating incontinence in the patient.

15. A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a therapeutic dose of an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, which oxybutynin is administered in up to 3 mg in 0 to 4 hours, 3 mg to 7.5 mg in 0 to 8 hours, 8 mg to 13 mg in 0 to 14 hours, and 12 mg to 15 mg in 0 to 24 hours for treating incontinence in the patient.

16. A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a dosage form comprising a therapeutic dose of oxybutynin that is administered in a sustained-release cumulative dose of 0.2% to 80% over 2 to 16 hours for treating incontinence.

17. The method for treating incontinence in a patient according to claim 16, wherein the therapeutic dose comprises 5 to 15 mg of oxybutynin.

18. The method for treating incontinence in a patient according to claim 16, wherein the dosage form is a pharmaceutically acceptable tablet.

19. A method for treating incontinence in a patient, wherein the method comprises administering orally to the patient a dosage form comprising a therapeutic dose of oxybutynin that is administered in a sustained release rate of 0.5% to 7% per hour over 30 minutes to 22 hours for treating incontinence.

20. The method for treating incontinence in a patient according to claim 19, wherein the therapeutic dose comprises 5 to 15 mg of oxybutynin.

21. The method for treating incontinence in a patient according to claim 19, wherein the dosage form is a pharmaceutically acceptable tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc